314 related articles for article (PubMed ID: 33742758)
1. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis.
Kai Y; Matsuda M; Fukuoka A; Hontsu S; Yamauchi M; Yoshikawa M; Muro S
Thorac Cancer; 2021 May; 12(9):1457-1460. PubMed ID: 33742758
[TBL] [Abstract][Full Text] [Related]
2. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
Shiratori T; Tanaka H; Tabe C; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Takanashi S; Tasaka S
Thorac Cancer; 2020 Jun; 11(6):1720-1723. PubMed ID: 32285615
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
4. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis.
Fukunaga K; Yokoe S; Kawashima S; Uchida Y; Nakagawa H; Nakano Y
Respirol Case Rep; 2018 Nov; 6(8):e00363. PubMed ID: 30237884
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.
Ikeda S; Ogura T; Kato T; Kenmotsu H; Agemi Y; Tokito T; Ito K; Isomoto K; Takiguchi Y; Yoneshima Y; Yokoyama T; Harada T; Tanzawa S; Kobayashi N; Iwasawa T; Misumi T; Okamoto H
Ann Am Thorac Soc; 2024 Apr; 21(4):635-643. PubMed ID: 38364204
[No Abstract] [Full Text] [Related]
8. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K; Kishimoto J; Ando M; Kenmotsu H; Minegishi Y; Horinouchi H; Kato T; Ichihara E; Kondo M; Atagi S; Tamiya M; Ikeda S; Harada T; Takemoto S; Hayashi H; Nakatomi K; Kimura Y; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakagawa K; Nakanishi Y; Okamoto I
Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 35361630
[TBL] [Abstract][Full Text] [Related]
9. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
Raghu G; Wells AU; Nicholson AG; Richeldi L; Flaherty KR; Le Maulf F; Stowasser S; Schlenker-Herceg R; Hansell DM
Am J Respir Crit Care Med; 2017 Jan; 195(1):78-85. PubMed ID: 27331880
[TBL] [Abstract][Full Text] [Related]
10. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib: first global approval.
McCormack PL
Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
13. Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.
Nakano A; Ohkubo H; Fukumitsu K; Fukuda S; Kanemitsu Y; Takemura M; Maeno K; Ito Y; Oguri T; Niimi A
Intern Med; 2019 Apr; 58(8):1141-1144. PubMed ID: 30568147
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S; Miyahara N; Taniguchi A; Oda N; Itano J; Higo H; Hara N; Watanabe H; Kano H; Suwaki T; Fuchimoto Y; Kajimoto K; Ichikawa H; Kudo K; Shibayama T; Tanimoto Y; Kuyama S; Kanehiro A; Maeda Y; Kiura K;
PLoS One; 2020; 15(8):e0236935. PubMed ID: 32853277
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
18. Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy.
Tahara M; Oda K; Yamasaki K; Kawaguchi T; Sennari K; Noguchi S; Sakamoto N; Kawanami T; Mukae H; Yatera K
BMC Pulm Med; 2019 Aug; 19(1):157. PubMed ID: 31438928
[TBL] [Abstract][Full Text] [Related]
19. Practical management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):90-8. PubMed ID: 26278687
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
